LARKSPUR, CA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)GLOBAL COALITION FOR ADAPTIVE RESEARCH INC, founded in 2017, is a mid-sized nonprofit in the Medical Research sector that reported $32.4M in total revenue in fiscal year 2025. Revenue grew 17% year-over-year, indicating healthy expansion.
OUR MISSION IS PIONEERING COLLABORATIVE, INNOVATIVE CLINICAL TRIALS TO SPEED THE DISCOVERY AND DEVELOPMENT OF CURES.
GBM AGILE (GLIOBLASTOMA ADAPTIVE GLOBAL INNOVATIVE LEARNING ENVIRONMENT) IS UNIQUELY DESIGNED AS A LONG-STANDING PLATFORM WITH THE ABILITY TO TEST MULTIPLE THERAPIES AT THE SAME TIME AGAINST A COMMON...
GBM AGILE (GLIOBLASTOMA ADAPTIVE GLOBAL INNOVATIVE LEARNING ENVIRONMENT) IS UNIQUELY DESIGNED AS A LONG-STANDING PLATFORM WITH THE ABILITY TO TEST MULTIPLE THERAPIES AT THE SAME TIME AGAINST A COMMON CONTROL (OR STANDARD OF CARE). THE PURPOSE IS TO EVALUATE MULTIPLE INVESTIGATIONAL TREATMENTS FOR EITHER NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA TO DETERMINE IF ANY OF THESE STUDY TREATMENT(S) IMPROVE OVERALL SURVIVAL AS COMPARED TO STANDARD TREATMENTS.
OTHER ONGOING PROGRAMS OR PROGRAMS IN DEVELOPMENT GCAR SERVES AS THE REGULATORY SPONSORSHIP OF THE MILITARY AND VETERANS PTSD ADAPTIVE PLATFORM CLINICAL TRIAL (M-PACT). PARTNERING WITH OPERATIONAL...
OTHER ONGOING PROGRAMS OR PROGRAMS IN DEVELOPMENT GCAR SERVES AS THE REGULATORY SPONSORSHIP OF THE MILITARY AND VETERANS PTSD ADAPTIVE PLATFORM CLINICAL TRIAL (M-PACT). PARTNERING WITH OPERATIONAL MEDICAL SYSTEMS, PART OF THE DEFENSE HEALTH AGENCY, GCAR IS CONDUCTING AN ADAPTIVE PLATFORM TRIAL AT IS EVALUATING MULTIPLE PHARMACOTHERAPEUTIC INTERVENTIONS FOR THE TREATMENT OF PTSD FOR ACTIVE-DUTY SERVICE MEMBERS AND VETERANS WITH PTSD AT MULTIPLE CLINICAL SITES IN THE US. THIS PROGRAM IS SUPPORTED BY A PROJECT TEAM THAT ALSO INCLUDES REPRESENTATIVES FROM THE U.S. AIR FORCE, ARMY, NAVY, AND SPECIAL OPERATIONS COMMAND. GCAR IS COMMITTED TO DESIGNING, LAUNCHING, AND OVERSEEING SEVERAL INITIATIVES CURRENTLY IN DEVELOPMENT TO RAPIDLY AND EFFICIENTLY EVALUATE NEW TREATMENTS FOR RARE AND LETHAL DISEASES, INCLUDING PANCREATIC CANCER, BILIARY TRACT CANCER, HIGH AND LOW GRADE SEROUS OVARIAN CANCER, AND NEUROFIBROMATOSIS. GCAR ALSO SUPPORTS EDUCATION, OUTREACH, AND CLINICAL COMMUNITY ENGAGEMENT TO ADDRESS THESE URGENT UNMET NEEDS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2025 | 2024 | Change | |
|---|---|---|---|
| Revenue | $32,444,163 | $27,688,488 | +0.2% |
| Expenses | $32,607,809 | $30,895,157 | +0.1% |
| Net Income | $-163,646 | $-3,206,669 | -0.9% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| GARY GORDON MD PHD | SENIOR MEDICAL ADVISOR AND DIRECTOR | 2.00 |
Director
|
$76,342 | $0 | $76,342 |
| TIMOTHY CLOUGHESY MD | CHIEF MEDICAL OFFICER AND DIRECTOR | 6.00 |
Officer
Director
|
$215,625 | $0 | $215,625 |
| WK ALFRED YUNG MD | DIRECTOR | 2.00 |
Director
|
$16,928 | $0 | $16,928 |
| FARAMARZ YOUSEFZADEH JD LLM | CHAIRMAN OF THE BOARD | 5.00 |
Director
|
$0 | $0 | $0 |
| BRIAN ALEXANDER MD MPH | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| SUJUAN BA PHD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| JOHN FRISHKOPF MMS | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| WEBSTER CAVENEE PHD | DIRECTOR | 2.00 |
Director
|
$0 | $0 | $0 |
| MATTHEW VIVA | DIRECTOR, LEGAL/SECRETARY | 40.00 |
Officer
|
$245,350 | $31,244 | $276,594 |
| MEREDITH BUXTON | CHIEF EXECUTIVE OFFICER/PRESIDENT | 40.00 |
Officer
|
$1,269,450 | $52,165 | $1,321,615 |
| RACHAEL COLEMAN | CFO/COO/TREASURER | 40.00 |
Officer
|
$541,250 | $31,098 | $572,348 |
| ASHLEY POWELL | VICE PRESIDENT, TRIAL OPERATIONS | 40.00 |
Key Emp
|
$520,625 | $13,882 | $534,507 |
| ROBERT MURRAY | CHIEF BUSINESS AND STRATEGY OFFICER | 40.00 |
Key Emp
|
$812,461 | $15,200 | $827,661 |
| RACHEL ROSENSTEIN SISSON | COMMUNITY ENGAGEMENT/TRAINING LEAD | 40.00 |
Highest
|
$266,440 | $19,558 | $285,998 |
| SARAH UNTCH | DIRECTOR, TRIAL OPERATIONS | 40.00 |
Highest
|
$246,909 | $29,119 | $276,028 |
| TRACEY ROBERTS | DIRECTOR, QUALITY AND NEW INITIATIVES | 40.00 |
Highest
|
$255,150 | $30,075 | $285,225 |
| HEATHER KLING | DIRECTOR, CLINICAL SCIENCE | 40.00 |
Highest
|
$216,304 | $20,013 | $236,317 |
| NAWEEN TAMJIDI | SR. MGR,TRIAL OPERATIONS | 40.00 |
Highest
|
$197,883 | $16,395 | $214,278 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $32,444,163 | $32,607,809 | $78,149,775 | $-163,646 |
| 2024 | No data | No data | No data | No data |
| 2023 | $28,779,160 | $29,710,627 | $59,610,730 | $-931,467 |
| 2022 | $35,373,148 | $24,083,323 | $59,575,227 | $11,289,825 |
| 2021 | $38,719,697 | $19,203,165 | $40,740,875 | $19,516,532 |
| 2020 | $15,863,066 | $10,452,245 | $28,309,589 | $5,410,821 |
| 2019 | $11,915,160 | $5,226,911 | $7,395,124 | $6,688,249 |
| 2018 | $2,525,750 | $2,468,396 | $109,128 | $57,354 |
Compare GLOBAL COALITION FOR ADAPTIVE RESEARCH INC with other nonprofits in California and across the country.